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Abstract
Background: Cancer cachexia is a syndrome of progressive weight loss. Non-small cell lung cancer patients
experience a high incidence of cachexia of 61%. Research into methods to combat cancer cachexia in various
tumour sites has recently progressed to the combination of agents.
The combination of the anti-cachectic agent Eicosapentaenoic acid (EPA) and the cyclo-oxygenase-2 (COX-2)
inhibitor celecoxib has been tested in a small study with some benefit. The use of progressive resistance training
(PRT) followed by the oral ingestion of essential amino acids (EAA), have shown to be anabolic on skeletal muscle
and acceptable in older adults and other cancer groups.
The aim of this feasibility study is to evaluate whether a multi-targeted approach encompassing a resistance training
and nutritional supplementation element is acceptable for lung cancer patients experiencing cancer cachexia.
Methods/Design: Auckland’s Cancer Cachexia evaluating Resistance Training (ACCeRT) is an open label,
prospective, randomised controlled feasibility study with two parallel arms. All patients will be treated with EPA
and the COX-2 inhibitor celecoxib on an outpatient basis at the study site. In the experimental group patients will
participate in PRT twice a week, followed by the ingestion of essential amino acids high in leucine. A total of 21
patients are planned to be enrolled. Patients will be randomised using 1:2 ratio with 7 patients enrolled into the
control arm, and 14 patients into the treatment arm. The primary endpoint is the acceptability of the above multi-
targeted approach, determined by an acceptability questionnaire.
Discussion: To our knowledge ACCeRT offers for the first time the opportunity to investigate the effect of
stimulating the anabolic skeletal muscle pathway with the use of PRT along with EAA alongside the combination
of EPA and celecoxib in this population.
Trial registration: Netherlands Trial Register (NTR): ACTRN12611000870954
Background
Cancer cachexia is a syndrome of progressive weight
loss, metabolic alterations, fatigue and persistent reduc-
tion of body cell mass in response to a malignant
tumour in the presence or absence of anorexia [1-3].
Cancer cachexia involves relatively similar losses of adi-
pose (fat) and muscle tissue which differs from simple
starvation or conditions such as anorexia nervosa, where
the majority of weight loss is from adipose rather than
muscle tissue [2,4-6].
The incidence of cachexia in cancer patients is depen-
d e n to nt h et y p ea n ds i t eo ft h et u m o u r ,a n dc a nr a n g e
from 31% to 87% of all cancer patients. While low inci-
dences are reported in Non-Hodgkin’s lymphoma, breast
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cer patients and over 85% in patients with gastric cancer
have been reported. Small-cell and Non-small-cell lung
cancer (NSCLC) patients also experience a high inci-
dence of cachexia, at 57% and 61% respectively [6-9]. It is
estimated that cachexia is present in up to 80% of cancer
patients at death, and the main cause of death in 20% of
all cancer patients [6,9].
Cancer cachexia is associated with a deterioration of
functional status and quality of life and is also associated
with poor survival [6]. Cachectic patients have lower
response rates to chemotherapy and shorter median sur-
vival [7]. While much of the cachectic weight loss is
from adipose tissue, it has been suggested that it is the
loss of muscle mass that accounts for mortality and
morbidity [10]. Muscle wasting is the main cause of
impaired function, leading to respiratory complications
and fatigue [11].
R e c e n t l yt h e r eh a sb e e nas h i f tf r o mt h eu s eo ft h e
cytotoxic platinum-based drug carboplatin to cisplatin in
the treatment of NSCLC. Cisplatin is associated with side
effects, amongst these cachexia and anorexia, thereby
confounding the symptom [12].
A recent review has shown that over the last few dec-
ades a number of studies have attempted to reduce
patients’ cachexia. This has involved the investigation of
several pharmacological agents. Unfortunately these stu-
dies demonstrated either no or limited benefit [13].
Research into methods to combat cachexia has therefore
recently progressed to the combination of agents e.g.
megestrol acetate and ibuprofen [14], Eicosapentaenoic
Acid (EPA) and nutritional supplements, nutritional sup-
port, anti-inflammatory and anaemia support, all again
with mixed results [13].
Such results would suggest that there is a need for a
new approach to the management of cancer cachexia.
Based on the literature for rheumatoid arthritis cachexia
group [15], older adults [16], and other cancer groups
[17,18] the combined use of anti-inflammatory agents,
improved food intake, especially protein and the perfor-
mance of progressive resistance training (PRT) anabolic
exercise, to stabilize the cachectic patient would appear
worthwhile investigating [13].
Non-steroid anti-inflammatory drugs (NSAID)
The use of NSAIDs in cancer patients is not widespread
due to concerns regarding cyclo-oxygenase-1 (COX-1)
inhibition, and its effect on gastrointestinal mucosal lin-
ing resulting in gastrointestinal bleeding and perforation
[19]. The development of selective COX-2 inhibitors has
led to the possibility of their use in reducing tumour-
mediated prostaglandin levels safely and could help alle-
viate or control cancer cachexia. The selective COX-2
inhibitor celecoxib has shown potent anti-tumour
growth inhibitory and anti-tumour preventive effects in
animal models [19].
The use of celecoxib has been investigated in eleven
cachectic patients with head and neck and gastrointest-
inal cancer [20]. Patients were randomised to celecoxib
200 mg twice daily or placebo for 3 weeks. The patients
on celecoxib reported good compliance and no adverse
events were seen [20]. Patients receiving celecoxib
showed a non-significant increase in body weight, (mean
change +1.0 kg compared with placebo group mean
change -1.3 kg), and a significant increase in mean
change score of the Quality of life (QoL) Functional
Assessment of Anorexia/Cachexia Treatment (FAACT)
questionnaire compared to a decrease in the placebo
group (P = 0.05). These results would appear to suggest
that only targeting inflammatory suppression may have
some benefits but will not produce a clinically significant
increase in lean body mass.
Recently, Mantovani and colleagues conducted a phase
II non-randomised prospective study investigating cele-
coxib at a dose of 300 mg per day for four months in
twenty-four advanced cancer patients (mixed tumour
sites) [21]. Results (see Table 1) showed a significant
decrease in the pro-inflammatory cytokine tumour necro-
sis factor-alpha (TNF-a) levels and a significant increase
in lean body mass (by bioelectrical impedance). Significant
improvements were also seen in QoL European Organiza-
tion for Research and Treatment of Cancer Quality of Life
Questionnaire-C30 (EORTC QLQ-C30), performance sta-
tus according to the Eastern Cooperative Oncology Group
(ECOG ) PS scale, Glasgow prognostic score (GPS) and
grip strength, along with good compliance and again no
grade 3 or 4 toxicities [21].
Eicosapentaenoic acid (EPA)
EPA is an omega-3 polyunsaturated fatty acid found in
oily fish which has been shown to have anti-tumour and
anti-cachexia activity in animal cachexia models [22,23].
A recent review examined the results for five hundred
and eighty-seven patients across five studies and found
Table 1 Endpoints from study investigating single agent
celecoxib by Mantovani et al [21]
Baseline After treatment p values
TNF-alpha (pg/ml) 36.8 ± 14.1 29.9 ± 12.2 0.007
LBM (Kg) 45.4 ± 6.7 45.8 ± 6.6 < 0.0001
QoL 66.3 ± 19.9 75.3 ± 10.1 0.024
ECOG PS 1.5 ± 0.67 1.2 ± 0.59 0.0023
GPS 1.3 ± 0.77 0.8 ± 0.7 0.0004
Grip strength 20. 8 ± 4.7 24.0 ± 5.5 0.004
TNF-alpha = Tumour Necrosis Factor-alpha, LBM = Lean body mass, QoL =
Quality of life, ECOG PS = Eastern Cooperative Oncology Group (ECOG)
Performance status, GPS = Glasgow prognostic score. Data are reported as
mean ± SD.
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benefit of EPA compared to placebo or to define the
optimal dose [24]. Internationally 2 g per day of EPA is
used as the ideal study dose in cancer cachexia studies
due to the following two studies [25,26]. Weight stability
has been shown with 2 g per day in eighteen unresect-
able pancreatic cancer patients. While all subjects
experienced progressive weight loss before treatment,
three quarters became either weight-stable, or gained
weight after treatment (P < 0.002) [26]. Furthermore,
Barber et al [25] reported a significant increase in lean
body mass with 2.1 g per day in twenty progressive
weight losing, unresectable pancreatic cancer patients
after 3 weeks (P = 0.024), and after 7 weeks of treatment
(P = 0.033) [25]. Overall it has been concluded from the
above review [24] along with the additional results from
a large double-blind, placebo-controlled study which
looked at EPA at two different dosages, that EPA on its
own has only marginal effects on cachexia and that it
should be used in combination with other agents [27].
Combined therapies
A range of clinical multimodal studies have been con-
ducted examining the combined effects of Ibuprofen and
megestrol acetate [14], COX-2 (celecoxib), Medroxypro-
gesterone acetate and oral food supplements [28], and
home total parenteral nutrition, anti-inflammatory (indo-
methacin) and erythropoietin therapy on cachexia [29].
COX-2 (celecoxib) and EPA
To date only one study has examined the potential bene-
fits of COX-2 inhibitors and EPA in reducing the effects
of cachexia. This study involved twenty-two advanced
stage IIIb-IV NSCLC patients randomised to 2 g per day
of fish oil/placebo vs. 2 g per day of fish oil/200 mg cele-
coxib twice daily [30].
Results indicated that thep a t i e n t si nb o t hg r o u p s
showed significantly less fatigue, lower C-reactive protein
(CRP) levels and increased appetite when compared to
their baseline values.
When comparing both groups, results showed signifi-
cantly higher increases in hand-grip scores and body
weights were seen in the fish oil/celecoxib group (Table 2).
Lean mass and fat mass also showed a trend of increasing
in this group [30]. Total dose of EPA used in this study
was 1.080 g per day, a value approximately half of previous
studies which used 2 g per day [25,26].
In the present study it was clinically decided that the
ingestion of EPA 2 g per day along with celecoxib would
be an acceptable control group medication.
Aetiology of muscle wasting
Muscle wasting is a combination and balance of the ana-
bolic and catabolic pathways, with decreased protein
synthesis combined with increased protein breakdown
[31]. It is hypothesised that the increase in protein degra-
dation may reflect the increased activity of the ubiquitin-
proteasome pathway and the lysosmal system, and that
the ubiquitin-proteasome pathway has the predominant
role in patients experiencing weight loss [8]. Conversely
the anabolic pathway involves the activation of the P13K/
Akt and mTOR pathway [32], leading to phosphorylation
and activation of its downstream target proteins, the
eukaryotic initiation factor 4E binding protein and p70
ribosomal S6 kinase 1 [8]. The decrease in protein synth-
esis is hypothesised to be due to changes to the phos-
phorylation of these initiation factors [8].
Progressive resistance exercise training (PRT)
While a variety of pharmacological approaches have been
examined for their ability to reduce or reverse cachexia in
humans, one approach that has been largely ignored is
that of PRT. This is most surprising as PRT has been
shown to be a potent stimulus for enhancing muscle
growth and strength and mass in a variety of groups
including athletes, older adults and for other cancer
groups [33]. PRT may down-regulate pro-inflammatory
cytokine activity and increase the phosphorylation of intra-
muscular amino acid signalling molecules mTOR and p70
ribosomal S6 kinase 1 [33].
PRT has been used in patients with well-controlled
rheumatoid arthritis with cachexia. This phase II study
reported that when PRT was performed an average 2.5
times a week for 12 weeks, significant increases in total
body skeletal muscle mass occurred with an adjusted
(post-test scores adjusted for pre-test scores) total lean
mass of 45.0 ± 0.3 kg in the training group and by 43.8 ±
0.3 in the control group (P= 0.005). PRT seemed to be a
safe and effective intervention with no exacerbation of the
activity of the disease [15].
Aerobic exercise and PRT has become popular in the
cancer community in recent years. There is now exten-
sive literature supporting PRT as the most effective
method for improving muscle function and strength, and
reducing the effects of sarcopenia in older adults [34].
Physical activity has showed consistent improvements in
patient rated QoL scores, by patients that are experiencing
Table 2 Endpoints from study investigating EPA/placebo
vs. EPA/celecoxib by Cerchietti et al [30]
Fish oil/placebo Fish oil/celecoxib p values
Grip strength 1.16 (0.3) 3.12 (0.95)* P = 0.002
Body weight (Kg) -1.4 (0.84) 1.5 (1.2)* P = 0.05
LBM (Kg) -0.6 (0.67) 0.4 (0.6) NS
Fat Mass (Kg) -0.6 (0.8) 1.2 (0.64) NS
LBM = Lean body mass. Data are recorded mean with SE in parentheses.*P <
0.02 compared to their respective baseline value.
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gated in patients with cancer, although mainly in the
breast cancer patient population [35]. A recent New Zeal-
and study described a positive relationship between quality
of life and physical activity in prostate cancer survivors on
androgen-deprivation therapy [36]. The positive relation-
ship between physical activity levels and quality of life in
these prostate cancer survivors concurs with the findings
of a systematic review examining body composition, func-
tional performance, QoL and physical benefit of exercise
in prostate cancer patients [17]. Results support the bene-
fits of exercise in improving muscular endurance, aerobic
endurance and overall QoL as well as reducing fatigue in
prostate cancer patients. This review also recommended
that the exercise performed should include a substantial
PRT component and be group-based to facilitate greater
psychosocial benefits [17]. A recent systematic review
examined the benefit of an exercise intervention on health
related QoL and exercise capacity specifically in NSCLC
patients [37]. Exercise interventions included resistance
training, stretching exercises, aerobic training and educa-
tion regarding exercise, under supervised or unsupervised
conditions. Sixteen studies involving thirteen patient
groups were assessed. The studies included two rando-
mised controlled trials and nine case series. It was con-
cluded that improvements were seen in patients’ exercise
capacity when participating in exercise pre-operatively.
For patients participating in exercise post-treatment,
improvements in exercise capacity was seen, but results
for health-related QoL were conflicting [37]. None of the
above studies looked at exercise in relation to the symp-
tom of cachexia.
Combined approach
In a recent review it has been shown that resistance exer-
cise and amino acids can independently stimulate skeletal
muscle synthesis and that muscle synthesis is greatly
increased if amino acids, especially leucine are ingested
after the resistance training exercise [38]. Studies in the
older adult have confirmed that providing this nutrition
after exercise increases muscle synthesis, although at a
slower rate, to levels similar to younger adults [38].
Recently an open non-randomized phase II study looked
at the efficacy and safety of an oral amino acid functional
cluster supplementation in twenty-five cachectic cancer
patients [39]. All patients had advanced cancer at mixed
tumour sites. The results of this study showed a significant
increase in grip strength (28.2 ± 9.5 vs. 30.4 ± 9.2, P <
0.0001), along with the trend of an increase in body weight
(Kg) (53.1 ± 10.6 vs. 54.2 ± 11.1, P = 0.056). Improved
levels of fatigue on the QoL multidimensional fatigue
symptom inventory-short form (MFSI-SF) were seen. A
decreasing score is associated with a lower level of fatigue
(25 ± 8.1 vs. 22 ± 7.3, P = 0.181). Decreasing CRP (24.7 ±
18.1 vs. 17 ± 11.4, P = 0.066) and interleukin-6 (IL-6 pg/
ml) levels (21.3 ± 16.4 vs. 13.7 ± 4, P =0 . 1 5 7 )w e r ea l s o
seen. This study suggests that amino acid supplementation
may be a beneficial option for the treatment of cancer
cachexia, and the integration of an amino acid supplemen-
tation into a multi-dimensional approach based on diet,
exercise, nutritional support and molecularly targeted
drugs for the management of cancer cachexia should be
the next step [39].
Such results provide further evidence that PRT is a
potent anabolic stimulus and that the anabolic response
to PRT can be augmented with pharmacological agents
that target selected aspects of the catabolic pathways.
The application of such a paradigm in cachectic cancer
patients would therefore warrant investigation.
Essential amino acids ± resistance training
Intravenous and orally administered amino acids have
been investigated in a number of settings in relation to
protein synthesis [40]. Exercise has been shown to also
have a profound effect on both muscle protein breakdown
and protein synthesis [40]. After reviewing oral composi-
tion studies [39-50], of ingestion doses between 6.7 g and
40 g, it was decided to use the amino acid composition
used by the studies of Fujita et al and Dreyer et al [47,50]
as reviewed in a recent systematic review (see table 3) [38].
Therefore, the ingestion dosage for the current investiga-
tion is 20 g.
Study rationale/purpose
The optimal treatment for cancer cachexia is the com-
plete removal of the tumour. Unfortunately in many
advanced solid tumours this is unachievable, especially
in the case of NSCLC patients. The next best options
are to increase nutritional intake and to counteract the
weight loss, address the anorexia and reduce inflamma-
tion, along with the metabolic alterations i.e. loss of
body fat and the skeletal muscle wasting [6,51].
Therefore, the current investigation aims to examine a
novel treatment regimen that may alleviate and/or
Table 3 Essential amino acids composition
Essential amino acid (g) %
Histidine 1.6 8%
Isoleucine 1.6 8%
Leucine 7.0 35%
Lysine 2.4 12%
Methionine 0.6 3%
Phenylalanine 2.8 14%
Threonine 2.0 10%
Valine 2.0 10%
Total 20.0 g 100%
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muscle anabolism with PRT and essential amino acids
high in leucine post exercise, the overall aim is to stabi-
lise the effect of muscle catabolism/anabolism to a net
gain in muscle mass. The investigation shall employ a
multi-targeted approach by utilizing data gained from
the literature to target and decrease the pro-inflamma-
tory cytokines by using a COX-2 inhibitor (celecoxib)
and decrease the ubiquitin proteolytic pathway with a
proteasome inhibitor EPA. This feasibility study is
required before recruiting to a full study to determine if
a multi-targeted therapy including PRT is acceptable to
this study population along with gaining data around
recruitment and retention and safety around this type of
clinical study. Variance and intra-patient correlation of
the secondary outcomes will then be used to power the
main study.
Methods/Design
Trial organisation
Auckland’s Cancer Cachexia evaluating Resistance Train-
ing (ACCeRT) is designed and coordinated by the Depart-
ment of General Practice and Primary Health Care,
University of Auckland, New Zealand. University of Auck-
land is responsible for overall trial management, regulatory
affairs, statistical planning and analysis, trial registration
(ACTRN12611000870954), and reporting as well as qual-
ity assurance. The trial will be performed at North Shore
Hospice, Auckland, New Zealand.
Participants
Twenty-one patients will be recruited from local hospice
day centres in Auckland and from referring clinicians
based at Auckland City Hospital, Auckland.
Medication supply
EPA will be supplied by Health World Limited, cele-
coxib (Celebrex) by Pfizer Australia and New Zealand,
and essential amino acids prepared by Musashi, Notting
Hill, Australia.
Ethics, informed consent and safety
The final protocol was approved by the Northern Y
Ethics Committee, Hamilton, New Zealand (NTY/11/06/
064) on the 2nd of September 2011. The clinical trial
complies with the Helsinki Declaration from 2008, the
Medical Association’s professional code of conduct, the
principles of Good clinical practice guidelines and the
Federal Data Protection Act.
Written informed consent for the clinical trial
ACCeRT will be obtained from each participating
patient in the oral and written form before inclusion in
the trial. The nature, scope and possible consequences
of the trial will be explained by a physician (or Principal
Investigator) in detail. The investigator will not under-
take any measures for the clinical trial until valid con-
sent has been obtained.
Study objectives
The primary objective of this clinical trial is to evaluate
whether a multi-targeted approach encompassing resis-
tance training element is acceptable for lung cancer
patients experiencing cancer cachexia. This will be
assessed by the analysis of a patient-rated Likert scored
questionnaire asking 10 questions on the acceptability of
the above multi targeted approach, both at week12/visit
5 and end of study visit.
Eligibility criteria
Inclusion criteria
1. Patients ≥ 18 years old
2.H i s t o l o g i c a lc o n f i r m e dn o n - s m a l lc e l lc a r c i n o m a
of the lung. Histological or cytological specimens
must be collected via surgical biopsy, brushing,
washing or core needle aspiration of a defined lesion.
Sputum cytology is not acceptable
3. Patients should be aware of the diagnosis of
cancer
4.P a t i e n t sa b l et og i v ew ritten informed consent
obtained according to local guidelines
5. Karnofsky Score (KS) ≥ 60 or ECOG Performance
Status 0,1, 2 or 3
6. Recently completed first-line platinum-based che-
motherapy (minimum of 1 month post last cycle)
7. Life expectancy ≥ 20 weeks
8. Fulfils the following ‘cachectic definition’
Patient selection
NSCLC cachectic patients as determined by the follow-
ing definition [52]
Q1 Has lost 5% of oedema-free body weight in the
previous 3-6 months
Q2 Classification of cachexia either Mild > 5%, Mod-
erate > 10%, Severe > 15% weight loss
Q3 If no documented weight loss, Is body mass index
< 20.0 kg/m
2
Q4 At least 3 out of the following 5
￿ Patient reported decreased muscle strength
￿ Fatigue as demonstrated in a maximum volume of
oxygen (VO2 max) test or patient reported reduced
physical activity
￿ Patient reported anorexia
￿ Low fat-free mass index (low muscle mass) by
bioelectrical impedance
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IL-6 > 4.0 pg/ml, haemoglobin < 12.0 g/dL or
hypoalbuminemia < 3.2 g/dL
Exclusion criteria
1. Concurrent use of other appetite stimulants e.g.
medroxyprogestrone acetate, megestrol acetate, 4 mg
daily dexamethasone or 30 mg daily prednisolone
2. Patients with systolic BP > 160 mmHg and/or dia-
stolic > 90 mmHg
3. Pleural effusion that causes ≥ CTC grade 2
dyspnoea
4.R a d i o t h e r a p y≤ 2 weeks prior to randomisation.
Patients must have recovered from all radiotherapy-
related toxicities
5. Patients having central nervous system (CNS)
metastases. Patients having any clinical signs of CNS
metastases must have a Computerised Tomography or
Magnetic resonance imagining (MRI) of the brain per-
formed to rule out CNS metastases in order to be eli-
gible for study participation. Patients who have had
brain metastases surgically removed or irradiated with
no residual disease confirmed by imaging are allowed
6. Patients with recent haemoptysis associated with
NSCLC (> 1 teaspoon in a single episode within 4
weeks)
Secondary objectives are
Secondary safety outcomes are: Serious Adverse Events
(SAEs) and Adverse Events (AEs);
GPS; KS; Progression-free survival (PFS) at the end of
the study; Overall compliance; Percentage of patients
eligible from total number recruited; Response evalua-
tion criteria in solid tumours (RECIST) data (if
available).
The following outcomes will be measured in this
study, for use in planning the main study, at the fol-
lowing time points: screening visit, week 1, 3, 6, 9, 12,
16 and 20 weeks after intervention commencement.
Secondary measured outcomes: Lean body mass
assessed by bioelectrical impedance analysis (Tanita BC-
418 Segmental Body Composition Analyzer, Tanita);
QoL and fatigue assessed by the following questionnaires
MFSI-SF, FAACT, and WHOQOL-BREF; Serum levels
of proinflammatory ‘classic cachexia cytokines’ (IL-1, IL-
6a n dT N F - a) measured by Bio-Plex Pro assay, Bio-Rad);
Hand grip strength assessed by hand grip dynamometry
of the dominant hand, the average of three attempts with
1 minute rest between attempts (Jamar); Leg grip
strength assessed by back/leg dynamometry of the right
leg, the average of three attempts with a 1 minute rest
between attempts (PE018 Back Dynamometer, Access
Health).
Secondary measured outcome MRI thigh skeletal mus-
cle values as assessed ‘blinded’ by University of Auckland
and Auckland District Health Board MRI departments.
Scans will be performed at screening visit and week 20
after intervention commencement only.
Randomisation and standardised treatment scheme
All patients enrolled will be identifiable throughout the
study. The investigator will maintain a personal list of
patient numbers and patient names. Upon consent each
patient will receive a unique identification number.
After the patient’s eligibility for randomisation has been
assessed he/she will be randomly assigned to one of the
two treatment arms in a 1: 2 ratio (EPA and celecoxib
vs. EPA and celecoxib, PRT and EAA).
Treatment scheme
Both study arms receive for a period of 20 weeks; 2.09 g
EPA Ethical Nutrients Hi-Strength Liquid Fish Oil oral
liquid (fruit punch flavour), 5.5 mls per day and 300 mg
per day of celecoxib.
Experimental group
Additionally, patients in the experimental group
undergo two sessions a week for 20 weeks of a tailored
PRT programme under the supervision of a trained
exercise therapist. All PRT sessions will be carried out
at North Shore Hospice. There will be a 5-10 minute
warm up, followed by the exercise prescription, and a 5
minute cool-down. 20 g of essential amino acids high in
leucine will be administered to the patients 1 hour after
PRT.
All patients are invited to continue with compassio-
nate use after the end of the study.
Evaluation and follow-up
All patients must have appropriate laboratory analysis
and MRI study conducted prior to study enrolment to
meet eligibility criteria. Laboratory parameters will be
obtained three weekly. The patient will be asked at each
visit for any adverse event (SAE and AE) as well as con-
comitant medication. QoL questionnaire (MFSI-SF,
FAACT and WHOQOL-BREF) will be handed out to
all patients on screening visit, weeks 1, 3, 6, 9, 12, 16
and 20.
Patients can withdraw from study participation at any
time. Patients will be taken off the study if unacceptable
toxicity appears. Unacceptable toxicity is defined as ser-
ious side effect or irreversible grade 3 toxicity. After the
individual ending of the study subjects will receive the
best available medical and nutritional care. Patients will
undergo MRI at the beginning and at the end of study.
Patients will be tracked and followed up until death.
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The intent-to-treat population including all patients who
are randomised with study medication assignment desig-
nated according to initial randomisation, regardless of
whether patients receive study medication or receive a dif-
ferent medication from that to which they were rando-
mised. This will be the primary population for evaluating
the acceptability, and measured outcome endpoints. The
safety population consisting of all patients who received at
least one dose of study medication or treatment.
Primary analysis
This will be assessed by the summary of a patient-rated
Likert scored questionnaire asking 10 questions on the
acceptability of the above multi targeted approach, both
at week12/visit 5 and end of study visit. Medians and
ranges will be estimated.
Secondary analysis
A l ls a f e t yo u t c o m e sw i l lb es u m m a r i s e db yg r o u p .E f f i -
cacy outcomes will be analysed using general or general-
ised linear mixed models to obtain estimates of
variances and co-variances for use in powering of a
future study. Group, time and their interaction will be
included as explanatory variables with a spatial covar-
iance structure across time. Trends over time will also
be examined to inform on the design of the future study
(timing of measures and the most appropriate outcome
measures).
Discussion
As outlined in the background section, patients with
advanced NSCLC patients experiencing cachexia often
result in a shorter life-expectancy and deterioration in
performance status and reduced QoL. There are data
indicating that a multi-targeted approach is the way for-
ward in this condition. This study aims to provide the
information required to conduct a full study to identify
a novel treatment regimen that will alleviate and/or sta-
bilise cancer cachexia weight loss and is acceptable to
patients with this condition. ACCeRT offers to our
knowledge for the first time the initial step required to
investigate the importance of stimulating the anabolic
skeletal muscle pathway with the use of PRT followed
by essential amino acids, alongside the use of this com-
bination of the anti-cachectic agent EPA and anti-
inflammatory drug celecoxib in this population.
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